RxDoctor Payments Data

Marian Holland, MD

Cardiovascular Disease · la Jolla, CANPI 1700084464

Payments from drug & device makers

$14,669in general payments, 2019–2025

Across 108 payments — averaging $135.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$3K
  • Abbott$744
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$119
  • Novartis$83
  • United Therapeutics Corporation$47
  • plus $243 from 8 others

What the payments were for

  • Travel & lodging$12,45885%
  • Food & beverage$2,21215%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,669 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$300,987
Medicare patients
2,801
Services billed
5,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin174$215,704
EliquisApixaban89$104,961
EntrestoSacubitril/Valsartan68$80,310
Repatha SureclickEvolocumab48$53,018
OzempicSemaglutide22$42,591
Praluent PenAlirocumab14$16,842
FarxigaDapagliflozin Propanediol11$16,027
NexlizetBempedoic Acid/Ezetimibe20$9,655
Ezetimibe95$3,213
Metoprolol Succinate156$2,437
Atorvastatin Calcium205$2,086
Spironolactone193$1,760
Rosuvastatin Calcium88$1,269
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,027
Amlodipine Besylate49$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$215,704174 claims
NovartisEntresto$83$80,31068 claims
Novo NordiskOzempic$39$42,59122 claims
AstraZenecaFarxiga$43$16,02711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →